Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Sage Therapeutics' stock craters 49% after FDA approves zuranolone for postpartum depression, but not major depressive disorder
08:01am, Monday, 07'th Aug 2023
Sage Therapeutics Inc.'s stock SAGE cratered 49% in premarket trade Monday, on disappointment that the U.S. regulator approved its zuranolone treatment for postpartum depression, but not for major dep
Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023
10:45pm, Friday, 04'th Aug 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a l
FDA approves first-ever pill for postpartum depression in new mothers
07:40pm, Friday, 04'th Aug 2023
The Food and Drug Administration late Friday approved the first-ever pill that can be taken at home for postpartum depression.
US FDA approves Biogen-Sage Therapeutics pill for clinical depression
07:11pm, Friday, 04'th Aug 2023
The U.S. Food and Drug Administration on Friday approved Biogen and Sage Therapeutics' oral pill for two common forms of depression, paving the way for patients to get a faster-acting therapy to treat
Why Sage Therapeutics Stock Is Tumbling Today
03:46pm, Wednesday, 26'th Jul 2023
Biogen's CEO downplayed the ongoing regulatory review for a Sage-partnered depression drug. The FDA is scheduled to hand down its decision by Aug. 5.
Sage Therapeutics: Zuranolone August Approval Likely, Opportunity Uncertain
01:15pm, Friday, 30'th Jun 2023
Sage Therapeutics, Inc. should find out in August whether its drug targeting major depressive disorder and postpartum depression, zuranolone, will be approved. Zuranolone is being co-developed with Bi
Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
06:30am, Monday, 05'th Jun 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will
Sage Therapeutics to Present at Upcoming May Investor Conferences
06:30am, Wednesday, 03'rd May 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will
Sage Therapeutics, Inc. (SAGE) Q1 2023 Earnings Call Transcript
03:28pm, Tuesday, 02'nd May 2023
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q1 2023 Earnings Conference Call May 2, 2023 8:00 AM ET Company Participants Helen Rubinstein - Director of Investor Relations Barry Greene - Chief Executive Off
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
09:08am, Tuesday, 02'nd May 2023
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $2.46 per share versus the Zacks Consensus Estimate of a loss of $2.50. This compares to loss of $2.07 per share a year ago.
Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
06:30am, Tuesday, 18'th Apr 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that
Sage Therapeutics to Present at the Stifel 2023 CNS Days
06:30am, Wednesday, 22'nd Mar 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that
Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock?
05:21am, Tuesday, 14'th Mar 2023
Sage Therapeutics, Inc. (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stren
Sage Therapeutics Looking To FDA Approval Of Zuranolone
06:23am, Tuesday, 21'st Feb 2023
Sage's first approved drug, Zulresso, did not sell well. Zuranolone offers significant improvements for depression over current therapies.
Sage Therapeutics, Inc. (SAGE) Q4 2022 Earnings Call Transcript
01:25pm, Thursday, 16'th Feb 2023
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Helen Rubinstein - Director of Investor Relations Barry Greene - Chief Executi
